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ABSTRACT
Introduction: Autosomal dominant polycystic kidney
disease (ADPKD) is the most common inherited kidney
disorder with numerous cysts developing in bilateral
kidneys. Meanwhile, ADPKD can also be regarded as a
systemic disease because the cystic and non-cystic
abnormalities could be identified in multiple organs in
patients with ADPKD. Several lines of evidence suggest
the risk of post-transplant diabetes mellitus or new-
onset diabetes after transplantation (NODAT) is higher
in patients with ADPKD compared with non-ADPKD
renal recipients, but the available results are
conflicting. We describe the protocol of a systematic
review and meta-analysis for investigating the risk of
NODAT in patients with ADPKD.
Methods and analysis: PubMed, EMBASE and The
Cochrane Library will be searched. Cohort studies
irrespective of language and publication status,
comparing the incidence of NODAT in renal recipients
with ADPKD and other kidney disease will be eligible.
We will assess heterogeneity among studies. Along
with 95% CIs, dichotomous data will be summarised
as risk ratios; numbers needed to treat/harm and
continuous data will be given as standard mean
differences. Excluding outliers and testing small
sample size studies if our results are robust, sensitivity
analysis will be carried out.
Ethics and dissemination: Ethical approval is not
required because this study includes no confidential
personal data or patient interventions. The review
findings will be helpful in designing and implementing
future studies and will be of interest to a wide range of
readers, including healthcare professionals,
researchers, health service managers and
policymakers. The systematic review will be published
in a peer-reviewed journal and disseminated
electronically and in print.
Trial registration number: The study protocol has
been registered in PROSPERO (http://www.crd.york.ac.
uk/PROSPERO/) under registration number
CRD42014009677.
INTRODUCTION
Autosomal dominant polycystic kidney
disease (ADPKD), as the most common,
potentially lethal monogenic inherited renal
disorder, occurs in 1:400 to 1:1000 live
births.1 2 ADPKD is caused by the mutation
in one of two genes: PKD1 or PKD2 in most
cases.3–5 Numerous ﬂuid-ﬁlled cysts progres-
sively grow in bilateral kidneys of the
patients. Besides kidney cysts, cystic and non-
cystic abnormalities can be found in multiple
organs and systems in patients with
ADPKD.6 7 As a result, ADPKD can be
regarded as a systemic disease. Previous
observational studies suggested that the pres-
ence of ADPKD was associated with compo-
nents of metabolic syndrome such as
hypertension, abdominal obesity and higher
fasting glycaemia.8 Even in the early stages of
ADPKD, decreased coronary ﬂow velocity
reserve, increased carotid intima media
thickness and increased insulin resistance
can be found,9 which suggests that the risks
of cardiovascular diseases and type 2 diabetes
are elevated in patients with ADPKD. The
reasons for metabolic abnormalities in
patients with ADPKD are not fully elucidated.
One reasonable explanation is that the func-
tion of polycystins might not be limited to
the preservation of normal nephron struc-
ture but also involved in metabolic adjust-
ment.10 The mutations of PKD1 or PKD2
might cause a genetic predisposition to meta-
bolic abnormalities.
End-stage renal disease (ESRD) occurs in
more than 70% of patients with ADPKD.11
As successful kidney transplantation can
correct the disturbance of the internal envir-
onment comprehensively, it is the preferred
option of renal replacement therapy.
Post-transplant diabetes mellitus or new-onset
diabetes after transplantation (NODAT) are
important complications after organ trans-
plantation due to the use of immunosuppres-
sive medications such as tacrolimus, CsA,
mTORi and corticosteroids.12–15 Several
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observations report that the risk of diabetes mellitus is
higher in patients with ADPKD compared with
non-ADPKD renal recipients. But the results from differ-
ent studies are conﬂicting; there are also studies suggest-
ing that ADPKD is not a risk factor for NODAT.16 17 The
relationship between ADPKD and an increased risk of
NODAT is far from being clariﬁed. This systematic
review and meta-analysis aims to comprehensively sum-
marise the available evidence about the risk of NODAT
in ADPKD renal recipients compared with non-ADPKD
recipients.
METHODS
The protocol of this review has been registered in
PROSPERO (CRD42014009677) (http://www.crd.york.
ac.uk/PROSPERO). The drafting of this protocol fol-
lowed the preferred reporting items for systematic review
and meta-analysis protocols (PRISMA-P) checklist.18
Search strategy and study selection
PubMed, EMBASE and The Cochrane Library will be
searched. No language or publication period restrictions
will be applied. The PubMed search strategy is shown in
box 1. The search terms will be adapted for the other
electronic data sources. We will also search the reference
lists of the original studies, letters to the editor, case
reports, guidelines, reviews and meta-analyses retrieved
through the electronic searches. We will perform our
search in April 2015 and update our search after ﬁnish-
ing the full review.
Types of study to be included
Cohort studies, irrespective of language and publication
status, will be included that compare the incidence of
NODAT in renal recipients with ADPKD and other
kidney diseases.
Types of participants
Inclusion criteria
Participants will include adult renal recipients. However,
patients who have impaired glucose regulation before
kidney transplantation (deﬁned as no positive ﬁnding in
fasting insulin, HbA1c or oral glucose tolerance test)
and patients who have received kidney–pancreas/
kidney–liver combined transplantation will be ineligible.
Type of exposure
Exposure
ESRD resulting from ADPKD. Diagnosis of ADPKD is
based on the detection of multiple cysts by renal ultra-
sound and a positive family history; patients with renal
cysts and negative family history with molecular genetic
testing conﬁrmed PKD1 or PKD2 mutation are also
eligible.
Type of control
Adult renal recipients with non-ADPKD ESRD.
Outcomes
Primary outcomes
Changes in biochemical indices relevant to diabetes
(such as HbA1c, GLU, fasting insulin) and changes in
renal manifestations (evaluated by biochemical markers
such as eGFR, creatinine clearance, serum creatinine,
urine albumin-to-creatinine ratio or dichotomous out-
comes such as the occurrence of urinary tract infection,
acute kidney injury, and other renal and urinary disor-
ders) will be analysed.
Secondary outcomes
Lipid metabolism, urate metabolism, survival of graft
and patients will be analysed as secondary outcomes.
Data extraction (selection and coding)
After completion of the literature search and review of
the titles and abstracts of all identiﬁed studies, we will
determine which articles require further consideration,
and then obtain the full records. Two authors will, inde-
pendently, assess the eligibility of each trial to be
included in the review, with the third author being con-
sulted to resolve disagreement. Data from each identi-
ﬁed study will be independently extracted and recorded
on a standardised data extraction form by two authors.
Disagreements will be resolved by discussion. When
requiring additional information, we will contact the ori-
ginal author of the studies. Details of the study selection
procedure are shown in ﬁgure 1.
The data to be extracted: ﬁrst author, year, journal,
study design, funding sources, study duration. Relevant
participants: (1) age; (2) sex; (3) disease status before
transplantation; (4) duration of kidney insufﬁciency; (5)
living/cadaveric kidney donor; (6) concomitant disease;
(7) immunosuppressive regiments. Relevant outcomes:
(1) biochemical indexes relevant to glucose metabolism
(HbA1c, 5FRG, fasting insulin); (2) biochemical indexes
assessing renal function (evaluated by biochemical
markers such as eGFR, creatinine clearance, serum cre-
atinine, urine albumin-to-creatinine ratio or dichotom-
ous outcomes such as the occurrence of urinary tract
infection, acute kidney injury, and other renal and
urinary disorders); (3) adverse events. When needed
data are missing, we will attempt to contact the original
investigators to obtain further information.
Risk of bias (quality) assessment
We will assess the risk of bias for each cohort study with
the Newcastle-Ottawa Quality Assessment Scale,19 accord-
ing to the quality in domains of cohort selection, com-
parability and outcome. A consensus will be reached to
Box 1 Search strategy for PubMed
#1 Kidney Transplantation
#2 Polycystic Kidney, Autosomal Dominant
#3 #1 and #2
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assess the risk of bias. With the Newcastle-Ottawa Quality
Assessment Scale, studies will be scored a maximum of
nine points on items including the selection of subjects,
the comparability between groups, and the ascertain-
ment of outcome of interest. Risk of bias for each
domain will be rated as high (seriously weakens conﬁ-
dence in the results), unclear or low (unlikely to ser-
iously alter the results).
Strategy for data synthesis
Using the I2 statistic and χ2 test (assessing the p value),
we will assess heterogeneity among studies.
Heterogeneity will be considered to be substantial
among the studies in which the p value is less than 0.10
and I2 exceeds 50%. We will combine the data with a
random effects model if signiﬁcant heterogeneity exists
(p<0.1; I2>50%). Along with 95% CIs, dichotomous data
will be summarised as risk ratio; however, numbers
needed to treat or harm and continuous data will be
given as standard mean difference. Excluding outliers
and testing small sample size studies if our results are
robust, a sensitivity analysis will be carried out. If the
data are so sparse that quantitative synthesis is not
appropriate, we will only carry out a systematic review.
Review Manager (RevMan) (computer programme),
V.5.3 (The Nordic Cochrane Centre, The Cochrane
Collaboration, Copenhagen, 2014) will be used to
generate forest plots. The funnel plots will be assessed
for evidence of asymmetry, and possible publication bias
or other small study effects. We will follow the Preferred
Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines in reporting our
ﬁndings.20
Analysis of subgroups or subsets
We plan to perform subgroup analyses according to the
disease classiﬁcation in control groups, immunosuppres-
sive regimens, duration of kidney insufﬁciency, living/
cadaveric kidney donor and concomitant disease. We
will speciﬁcally analyse diseases known to be metabolism
related, such as hypertensive nephropathy, obesity and
mutations in HNF1 α/β.
Risk of bias across studies
The possibility of publication bias will be assessed visu-
ally using funnel plots in which non-publication of small
trials with negative results could result in asymmetry, and
formally with Egger’s test. In funnel plots, the effect of
each trial will be plotted by the inverse of its standard
error.
Confidence in cumulative evidence
We will assess the quality of the body of evidence using
the principles of the GRADE system.21 We will construct
Figure 1 Flow diagram of
studies included.
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a Summary of Findings table using the GRADE software.
The GRADE approach will appraise the quality of a
body of evidence based on the extent to which one can
be conﬁdent that an estimate of effect or association
reﬂects the item being assessed. The quality of a body of
evidence assessment considers within-study risk of bias
(methodological quality), the directness of the evidence,
the heterogeneity of the data, the precision of effect esti-
mates and the risk of publication bias.
DISCUSSION
In recent clinical studies and reviews, it was suggested
that the incidence of glucose metabolic disorders after
kidney transplantation in patients with ADPKD is higher
than in those with other kidney diseases.22 Some authors
even proposed potential mechanisms23 24 to explain this
ﬁnding.
However, there is still no robust evidence supporting
the association between ADPKD and NODAT, and the
available data are conﬂicting. To further clarify this asso-
ciation, we present a protocol of a systematic review to
determine the risk of NODAT in renal recipients with
ADPKD compared with non-ADPKD recipients. The
conclusions drawn from this review will beneﬁt the
design and implementation of future studies and will be
of interest to a wide range of readers, including health-
care professionals, researchers, health service managers
and public policy makers.
There are several strengths of this review. The review
question is an important clinical issue closely correlated
to further research, and our extensive search of the rele-
vant literature will provide a comprehensive assessment
of the review question. This review will be the ﬁrst high-
quality systematic review and meta-analysis to summarise
current evidence on the occurrence of new onset dia-
betes after kidney transplantation in patients with
ADPKD. Some potential limitations should be discussed.
The poor quality and heterogeneity of the primary
studies which might appear in our future analysis are
the most common reasons for downgrading the quality
of evidence. Challenges in optimising search terms,
poor indexing of studies, limitations of databases used
or the existence of grey literature will also prevent us
from collecting comprehensive data.
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